Phase 1/2 trial of Darovasertib With or Without Binimetinib Is Feasible, Safe for Metastatic Uveal Melanoma

Source: cancernetwork, April 2021

Treatment with the selective inhibitor of protein kinase C darovasertib (IDE196) as monotherapy in patients with heavily pretreated metastatic uveal melanoma (MUM) resulted in a 1-year overall survival (OS) rate of 57% (95% CI, 44%-69%), according to Ideaya Biosciences, Inc. who is responsible for developing the agent.

Clinical data released from the phase 1/2 trial (NCT03947385) also show the agent’s activity in combination with the MEK inhibitor binimetinib (Mektovi), which was able to induce responses in certain patients.

READ THE ORIGINAL FULL ARTICLE
Menu